- Home
- IBTA vs XNCR Comparison
IBTA vs XNCR Comparison
Compare IBTA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- XNCR
- Stock Information
- Founded
- IBTA 2011
- XNCR 1997
- Country
- IBTA United States
- XNCR United States
- Employees
- IBTA N/A
- XNCR N/A
- Industry
- IBTA
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- XNCR Health Care
- Exchange
- IBTA Nasdaq
- XNCR Nasdaq
- Market Cap
- IBTA 926.1M
- XNCR 1.1B
- IPO Year
- IBTA 2024
- XNCR 2013
- Fundamental
- Price
- IBTA $28.97
- XNCR $14.00
- Analyst Decision
- IBTA Hold
- XNCR Buy
- Analyst Count
- IBTA 9
- XNCR 11
- Target Price
- IBTA $38.75
- XNCR $24.50
- AVG Volume (30 Days)
- IBTA 275.6K
- XNCR 1.5M
- Earning Date
- IBTA 11-12-2025
- XNCR 11-05-2025
- Dividend Yield
- IBTA N/A
- XNCR N/A
- EPS Growth
- IBTA 2512.20
- XNCR N/A
- EPS
- IBTA 2.84
- XNCR N/A
- Revenue
- IBTA $367,604,000.00
- XNCR $157,218,000.00
- Revenue This Year
- IBTA N/A
- XNCR $22.09
- Revenue Next Year
- IBTA $0.58
- XNCR N/A
- P/E Ratio
- IBTA $10.17
- XNCR N/A
- Revenue Growth
- IBTA 3.49
- XNCR 54.77
- 52 Week Low
- IBTA $22.50
- XNCR $6.92
- 52 Week High
- IBTA $79.80
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- IBTA 36.09
- XNCR 54.37
- Support Level
- IBTA $32.06
- XNCR $13.30
- Resistance Level
- IBTA $35.23
- XNCR $15.50
- Average True Range (ATR)
- IBTA 1.23
- XNCR 1.16
- MACD
- IBTA -0.60
- XNCR -0.17
- Stochastic Oscillator
- IBTA 2.14
- XNCR 48.72
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.